Health Canada Approves Celltrion’s Omlyclo™ (CT-P39), Canada’s First Omalizumab Biosimilar
Celltrion announced today that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is now approved for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also…